Preservation of the Whole Matrix: Traditional PRP systems use a centrifuge to strip away red and white blood cells, leaving only concentrated platelets.

The ActiGraft Advantage: ActiGraft uses unmanipulated whole peripheral blood, meaning it preserves the entire cellular architecture—including red blood cells, white blood cells, platelets, cytokines, and a dense fibrin matrix. This acts as a fully functional, living extracellular matrix (ECM) to replace the damaged, stalled tissue in chronic wounds.

No Capital Equipment: Unlike PRP, ActiGraft requires no centrifuge and no expensive machinery to prepare.

Yes. Patient anticoagulation therapy is not a barrier to treatment. ActiGraft can be successfully prepared from the peripheral blood of patients actively taking prescription blood thinners.

Yes, absolutely. ActiGraft and ActiGraftPro are 100% autologous—created exclusively from the patient's own blood. The systems contain zero bovine (cow), porcine (pig), placental, or third-party human tissue, making them an inclusive choice for patients with strict religious or cultural medical restriction.

ActiGraft is FDA-cleared for the management of chronic, exuding cutaneous wounds. This includes:

• Diabetic Foot Ulcers (DFUs)
• Venous Leg Ulcers (VLUs) and arterial ulcers
• Pressure Injuries (Stage 3 and 4 bedsores)
• Mechanically or surgically debrided wounds

Yes. Unlike many alternative biological skin substitutes, the activated blood clot scaffold can be safely applied directly over wounds with exposed bone and tendon.

ActiGraft should not be used on:

• Wounds resulting from active malignancy
• Wounds with active, clinically diagnosed infections

Under professional supervision, the whole blood clot is topically applied to the wound bed once every 5 to 7 days as part of a comprehensive weekly wound management visit.

The primary difference between ActiGraft and traditional Platelet-Rich Plasma (PRP) systems lies in their preparation process and the composition of the final product applied to the wound.

Key Differences:

• Whole Blood vs. Isolated Plasma:PRP Systems: These use a centrifuge to spin down blood and isolate only the platelet-rich plasma. In this process, other vital components—such as red blood cells, white blood cells, and extracellular matrix (ECM) components—are discarded.ActiGraft: This system uses the patient's whole blood. By mixing the blood with a proprietary coagulation powder, it retains all cellular and structural components—including platelets, red and white blood cells, and the extracellular matrix—to create a "whole blood clot".
• Equipment and Workflow:PRP Systems: Generally require a centrifuge, which involves significant equipment investment, specific training, and longer preparation times.ActiGraft: It is a centrifuge-free procedure. It can be prepared at the point of care in approximately 5 minutes, significantly reducing workflow disruption.
• Clinical Evidence:ActiGraft: It is unique in its category for being backed by published, peer-reviewed randomized controlled trial (RCT) evidence, which demonstrated 173% more patients healed compared to the standard of care. Many competing PRP-based systems lack such peer-reviewed RCT data.
• Versatility:ActiGraft: Because it uses whole blood, it can be effective even in patients on anticoagulation therapy (blood thinners). It is also designed to work on large, irregular wounds and can be applied even in the presence of exposed bone or tendon.

In summary, ActiGraft aims to recreate the body’s natural healing environment by preserving the complete composition of the blood, whereas traditional PRP focuses on concentrating platelets while removing other blood components.

No, ActiGraft does not require cold storage. It is designed to be stored at a controlled room temperature, specifically between 5°C and 30°C (41°F–86°F).

You should protect the product from freezing and avoid exposing it to excessive heat. Because it is stored at room temperature, it is highly convenient for office and mobile providers who may not have access to specialized refrigeration.

ActiGraft is not limited to chronic wounds; it is FDA-cleared for the management of both chronic and acute exuding cutaneous wounds.

While it is frequently associated with difficult-to-heal chronic conditions like diabetic ulcers and pressure injuries, it is also beneficial for acute wounds, including those resulting from mechanical or surgical debridement.

Why it is used for both:

• Healing Mechanism: Whether a wound is chronic or acute, ActiGraft’s whole blood clot gel acts as a biologic scaffold and protective covering. It provides a moist microenvironment that promotes the body's natural healing processes.
• Transforming the Environment: ActiGraft is often used to help transition wounds—particularly chronic ones—from a non-healing state into a healing "acute" environment.
• Versatility: It is indicated for a wide variety of open cutaneous and soft tissue wounds. In clinical practice, it has been used successfully for diverse cases, including post-amputation surgical sites and complex wounds with exposed structures.

Important Note: ActiGraft should always be used under the supervision of a healthcare professional and in conjunction with standard wound management procedures (such as debridement, infection management, and off-loading). It is contraindicated for wounds due to malignancy or those with an active, clinically diagnosed infection.

Yes, ActiGraft can be shaped and trimmed to fit the specific needs of the wound bed.

Because the product forms a cohesive, whole-blood-derived clot gel, it is physically versatile for the clinician:

• Versatile Application: The clot can be carefully managed or trimmed by the healthcare professional to match the dimensions and depth of the wound.
• Conforming to Irregular Shapes: Its gel-like consistency allows it to conform easily to irregular wound beds, including tunnels, undermining, or complex surface shapes, which is a major advantage over pre-formed dressings.
• Maintained Integrity: Even when adjusted, it retains its structure to act as a supportive, protective scaffold across the site.

This ability to tailor the application ensures that the entire wound area receives the benefit of the biologic scaffold while allowing for the precise management of wound margins.

The ActiGraft system is designed to provide consistent healing outcomes across its various configurations, including the "Flowable" version.

Both the standard scaffold (often referred to as the whole blood clot) and the Flowable version leverage the same autologous, whole-blood-derived technology. The primary purpose of the Flowable version is to provide the same biological healing components in a format that is easier to apply to specific types of wounds—such as deep tunneling, undermining, or irregular cavities—where a pre-formed clot might not achieve full contact.

Key points regarding efficacy:

• Biological Consistency: Both versions contain the same essential components derived from the patient's own whole blood (platelets, fibrin matrix, growth factors, red and white blood cells, and minerals), ensuring that the underlying "healing cascade" remains the same regardless of the physical delivery method.
• Tailored Application: The "Flowable" configuration is essentially an adaptation of the ActiGraft technology designed to improve clinical utility in complex wound geometries, not a separate therapy with different healing properties.
• Clinical Outcomes: Because the underlying biological mechanism (reactivating the body’s natural healing cascade via a whole blood clot) is identical, the clinical expectation for healing is consistent with the proven results seen in ActiGraft’s randomized controlled trials.

In essence, the Flowable version is a tool for better delivery to help you achieve the same reliable outcomes in wounds where a flat or standard-sized clot may not be the optimal physical fit. If you have specific cases involving tunneling or deep undermining, the Flowable version is generally the preferred choice to ensure the "scaffold" reaches every part of the wound bed.

Yes, ActiGraft has been utilized in clinical practice to assist in the reconstruction and management of soft tissue deficits.

While ActiGraft is FDA-cleared for the topical management of exuding cutaneous wounds (such as diabetic ulcers, venous leg ulcers, pressure ulcers, and surgically or mechanically debrided wounds), its application in cases involving tissue loss is well-documented in clinical case studies.

Here is how it functions in these scenarios:

• Biologic Scaffold: When applied to a wound with a tissue deficit, the whole blood clot acts as a temporary extracellular matrix (ECM). This scaffold recruits the patient’s own cells—such as fibroblasts and endothelial cells—which are essential for constructing new, permanent tissue.
• Granulation Promotion: Clinical evidence shows that ActiGraft promotes extensive granulation tissue growth, which can help fill in voids, cover exposed structures like bone or tendon, and revitalize macerated or necrotic tissue.
• Wound Bed Preparation: In many surgical or complex trauma cases, ActiGraft is used to "prepare" a wound bed that has a significant tissue deficit. By reducing necrotic tissue and filling the deficit with healthy granulation tissue, it creates a viable environment for subsequent procedures, such as definitive skin grafting.

Because the clot is autologous (derived from the patient's own blood), it integrates into the site and helps "fill in" the disruption caused by injury or surgical debridement, initiating the body's natural healing cascade to mend the soft tissue deficit.